NCT06128629Phase 3Recruiting

MAGNITUDE: A Phase 3 Study of NTLA-2001 in Participants With Transthyretin Amyloidosis With Cardiomyopathy (ATTR-CM)

Study sponsor: Intellia Therapeutics

Primary completion is the date data collection ends for the main study measures, not when results are published.

Primary completion2027-12Estimated
Enrollment · participants1200Estimated
Source updated2026-11-04Last update listed in the registry record

Changes to this trial

Last 12 months
Filters
Clear filters

· 1 field changed

Recruitment status changed

Before: Active not recruiting. After: Recruiting.

Check registry source

· 2 fields changed

Planned enrollment increased by 435 participants

Before: 765 participants (planned). After: 1200 participants (planned).

Recruitment status changed

Before: Recruiting. After: Active not recruiting.

Check registry source

Explore older trial changes

Upgrade to Pro to see the full available history for this trial.

Upgrade to Pro Illustrative preview